MMAD-d8
PRODUCTS SPECIFICATIONS
DESCRIPTION
Overview
| MDL | - |
|---|---|
| Molecular Weight | 779.11 |
| Molecular Formula | C41H58D8N6O6S |
| SMILES | O=C(N[C@H](C1=NC=CS1)CC2=CC=CC=C2)[C@H](C)[C@@H](OC)[C@H]3N(C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C([C@@](C([2H])(C([2H])([2H])[2H])C([2H])([2H])[2H])([2H])NC([C@H](C(C)C)NC)=O)=O)C)=O)CCC3 |
Summary
D8-MMAD is a deuterated form of MMAD, which is a microtubule disrupting agent.
IC50 & Target
|
Auristatin |
In Vitro
MMAD (Monomethyl Dolastatin 10) is coupled through a stable oxime-ligation process to yield several near-homogenous antibody-drug conjugates (ADCs) with a drug-to-antibody ratio of ~2.0. The resulting conjugates demonstrate good pharmacokinetic properties, potent in vitro cytotoxic activity against HER2+ cancer cells. When compared with ADCs prepared by cysteine alkylation following native interchain disulfide reduction, site-specific unnatural-amino-acid-based ADCs are shown to have increased in vitro cytotoxicity [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
The resulting antibody-drug conjugates (ADCs) demonstrate complete tumour regression in rodents. They also have an improved toxicology profile in rats [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years |
* The compound is unstable in solutions, freshly prepared is recommended.
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 128.35 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.2835 mL | 6.4176 mL | 12.8352 mL |
| 5 mM | 0.2567 mL | 1.2835 mL | 2.5670 mL |
| 10 mM | 0.1284 mL | 0.6418 mL | 1.2835 mL |
